|
1
|
Rainov NG and Heidecke V: Clinical
development of experimental therapies for malignant glioma. Sultan
Qaboos Univ Med J. 11:5–28. 2011.PubMed/NCBI
|
|
2
|
Dong J, Wang XQ, Yao JJ, Li G and Li XG:
Decreased CUL4B expression inhibits malignant proliferation of
glioma in vitro and in vivo. Eur Rev Med Pharmacol Sci.
19:1013–1021. 2015.PubMed/NCBI
|
|
3
|
Norden AD, Drappatz J and Wen PY:
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol.
5:610–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Castro MG, Candolfi M, Kroeger K, King GD,
Curtin JF, Yagiz K, Mineharu Y, Assi H, Wibowo M, Ghulam Muhammad
AK, et al: Gene therapy and targeted toxins for glioma. Curr Gene
Ther. 11:155–180. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fuertes M, Gerez J, Haedo M, Giacomini D,
Páez-Pereda M, Labeur M, Stalla GK and Arzt E: Cytokines and genes
in pituitary tumorigenesis: RSUME role in cell biology. Front Horm
Res. 38:1–6. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carbia-Nagashima A, Gerez J, Perez-Castro
C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F and Arzt E:
RSUME, a small RWD-containing protein, enhances SUMO conjugation
and stabilizes HIF-1alpha during hypoxia. Cell. 131:309–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fowkes RC and Vlotides G: Hypoxia-induced
VEGF production ‘RSUMEs’ in pituitary adenomas. Endocr Relat
Cancer. 19:C1–C5. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gerez J, Fuertes M, Tedesco L, Silberstein
S, Sevlever G, Paez-Pereda M, Holsboer F, Turjanski AG and Arzt E:
In silico structural and functional characterizations of the RSUME
splice variants. PLoS One. 8:e577952013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chan JY, Tsai CY, Wu CH, Li FC, Dai KY,
Sun EY, Chan SH and Chang AY: Sumoylation of hypoxia-inducible
factor-1α ameliorates failure of brain stem cardiovascular
regulation in experimental brain death. PLoS One. 6:e173752011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhattacharyya SN, Habermacher R, Martine
U, Closs EI and Filipowicz W: Stress-induced reversal of microRNA
repression and mRNA P-body localization in human cells. Cold Spring
Harb Symp Quant Biol. 71:513–521. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li R and Li X, Ning S, Ye J, Han L, Kang C
and Li X: Identification of a core miRNA-pathway regulatory network
in glioma by therapeutically targeting miR-181d, miR-21, miR-23b,
β-Catenin, CBP, and STAT3. PLoS One. 9:el019032014.
|
|
15
|
Wang L, Shi ZM, Jiang CF, Liu X, Chen QD,
Qian X, Li DM, Ge X, Wang XF, Liu LZ, et al: MiR-143 acts as a
tumor suppressor by targeting N-RAS and enhances
temozolomide-induced apoptosis in glioma. Oncotarget. 5:5416–5427.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rathod SS, Rani SB, Khan M, Muzumdar D and
Shiras A: Tumor suppressive miR-34a suppresses cell proliferation
and tumor growth of glioma stem cells by targeting Akt and Wnt
signaling pathways. FEBS Open Bio. 4:485–449. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang C, Shi H, Wang C, Wang J, Geng N,
Jiang X and Wang X: Correlation of microRNA-375 downregulation with
unfavorable clinical outcome of patients with glioma. Neurosci
Lett. 531:204–208. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shan B, Gerez J, Haedo M, Fuertes M,
Theodoropoulou M, Buchfelder M, Losa M, Stalla GK, Arzt E and
Renner U: RSUME is implicated in HIF-1-induced VEGF-A production in
pituitary tumour cells. Endocr Relat Cancer. 19:13–27. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Benderro GF, Sun X, Kuang Y and Lamanna
JC: Decreased VEGF expression and microvascular density, but
increased HIF-1 and 2α accumulation and EPO expression in chronic
moderate hyperoxia in the mouse brain. Brain Res. 1471:46–55. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li R, Wei J, Jiang C, Liu D, Deng L, Zhang
K and Wang P: Akt SUMOylation regulates cell proliferation and
tumorigenesis. Cancer Res. 73:5742–5753. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Capili AD and Lima CD: Structure and
analysis of a complex between SUMO and Ubc9 illustrates features of
a conserved E2-Ubl interaction. J Mol Biol. 369:608–618. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rapino C, Bianchi G, Di Giulio C,
Centurione L, Cacchio M, Antonucci A and Cataldi A: HIF-1alpha
cytoplasmic accumulation is associated with cell death in old rat
cerebral cortex exposed to intermittent hypoxia. Aging Cell.
4:177–185. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Melchior F: SUMO-nonclassical ubiquitin.
Annu Rev Cell Dev Biol. 16:591–626. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vertegaal AC, Ogg SC, Jaffray E, Rodriguez
MS, Hay RT, Andersen JS, Mann M and Lamond AI: A proteomic study of
SUMO-2 target proteins. J Biol Chem. 279:33791–33798. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei R, Yang Q, Han B, Li Y, Yao K, Yang X,
Chen Z, Yang S, Zhou J, Li M, et al: microRNA-375 inhibits
colorectal cancer cells proliferation by downregulating JAK2/STAT3
and MAP3K8/ERK signaling pathways. Oncotarget. 8:16633–16641.
2017.PubMed/NCBI
|
|
26
|
Tsukamoto Y, Nakada C, Noguchi T, Tanigawa
M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M and
Moriyama M: MicroRNA-375 is downregulated in gastric carcinomas and
regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer
Res. 70:2339–2349. 2010. View Article : Google Scholar : PubMed/NCBI
|
